Michael Kuefner

Company: Arbor Biotechnologies, Inc.

Job title: Principal Scientist

Seminars:

1:30 ABO-101, a novel gene editing therapy for primary hyperoxaluria type 1, is efficacious and well tolerated in NHPs and results in high fidelity editing in primary hepatocytes 1:30 pm

Single administration of ABO-101 to NHPs results in efficient HAO1 editing, reduced GO enzyme activity, and no clinical signs or adverse events mABO-101, a mouse surrogate of ABO-101, demonstrated efficient in vivo editing and reduction of urinary oxalate in juvenile and adult Agxt KO mice ABO-101 is an efficient and specific HAO1 gene editor in…Read more

day: Conference Day 2